Studies have shown that patients with bevacizumab-resistant CRC exhibit increased levels of histone lactylation, which promotes the transcription of recombinant rubicon-like autophagy enhancer (RUBCNL) through interactions with beclin 1 (BECN1). Here, BECN1 is linked to colorectal carcinoma.